Short Interest in XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Grows By 286.4%

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) was the target of a large increase in short interest in July. As of July 15th, there was short interest totaling 36,172 shares, an increase of 286.4% from the June 30th total of 9,362 shares. Based on an average daily trading volume, of 57,229 shares, the short-interest ratio is currently 0.6 days. Approximately 2.3% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of XTL Biopharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. One analyst has rated the stock with a Sell rating, According to MarketBeat, XTL Biopharmaceuticals currently has a consensus rating of “Sell”.

XTL Biopharmaceuticals Stock Performance

XTLB traded up $0.04 on Friday, hitting $2.94. 1,415 shares of the company were exchanged, compared to its average volume of 200,273. XTL Biopharmaceuticals has a 12 month low of $2.01 and a 12 month high of $10.28. The company has a market cap of $6.47 million, a PE ratio of -4.59 and a beta of 1.45. The stock’s fifty day moving average is $2.59 and its 200-day moving average is $2.87.

XTL Biopharmaceuticals (NASDAQ:XTLB) last released its quarterly earnings data on Tuesday, June 30th. The biopharmaceutical company reported ($0.10) EPS for the quarter. The firm had revenue of ($0.26) million during the quarter.

XTL Biopharmaceuticals Company Profile

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.